Tafinlar/Mekinist (dabrafenib/trametinib)

pCPA File Number: 21500
Negotiation Status:
Active Negotiation
Indication(s):
Non-small cell lung cancer: for the treatment of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CADTH Project Number:
PC0226-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable